Drug Trial Radar · NCT04455841
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Mar 19, 2021
Primary completion
Apr 1, 2025
Study completion Sep 8, 2026
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jul 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Conditions
- Anemia
- Post-essential Thrombocythemia Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
Interventions
INCB000928Drug
INCB000928 will be administered at protocol defined dose.
ruxolitinibDrug
Ruxolitinib will be administered at protocol defined dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)Time frame: up to approximately 4 years
- Number of Participants With Any ≥Grade 3 TEAE and Any Treatment-emergent SAETime frame: up to approximately 4 years
- Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: from Cycle 1 Day 1 to Cycle 1 Day 28
- Maximum Tolerated Dose (MTD)Time frame: from Cycle 1 Day 1 to Cycle 1 Day 28
- Recommended Dose for Expansion (RDE)Time frame: from Cycle 1 Day 1 to Cycle 1 Day 28
Locations
34 sites in 6 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
City of Hope Orange County
Irvine, California
Usc Norris Comprehensive Cancer Center
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
Prebys Cancer Center
San Diego, California
Emory University - Winship Cancer Institute
Atlanta, Georgia
Emory University-Winship Cancer Institute
Atlanta, Georgia
Start Midwest
Grand Rapids, Michigan
Washington University School of Medicine
St Louis, Missouri
Weill Cornell Medical Centers
New York, New York
Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
Durham, North Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Md Anderson Cancer Center
Houston, Texas
Princess Margaret Cancer Center
Toronto, Ontario, Canada
McGill University Jewish General Hospital
Montreal, Quebec, Canada
Centre Hospitalier D'Angers
Angers, France
Institut Paoli Calmettes
Marseille, France
Hospital Saint Louis
Paris, France
Azienda Ospedaliera Papa Giovanni Xxiii
Bergamo, Italy
S Orsolas University Hospital Seragnoli Institute of Hematology
Bologna, Italy
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano
Orbassano, Italy
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
Pavia, Italy
Ospedale Santa Maria Della Misericordia Perugia
Perugia, Italy
Tokyo Medical and Dental University Hospital
Bunkyō City, Japan
Chiba Cancer Center
Chiba, Japan
Gifu Municipal Hospital
Gifu, Japan
Kansai Medical University Hospital
Hirakata, Japan
Kumamoto Shinto General Hospital
Kumamoto, Japan
Osaka International Cancer Institute
Osaka, Japan
United Lincolnshire Hospitals
Boston, United Kingdom
Lincoln County Hospital
Lincoln, United Kingdom
Royal Cornwall Hospital Truro Sunrise Centre
Truro, United Kingdom
University Hospital of Wales
Cardiff, WLS, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.